Dupilumab for a Novel Treatment for Necrobiosis Lipoidica: Case Report
Background This paper describes a case of necrobiosis lipoidica (NL) which was successfully treated with dupilumab. NL can be a difficult and chronic disease, often with limited treatment options. Dupilumab is a biologic typically used for atopic dermatitis, but given its novel pathway, it has been used in a number of other conditions. Case Presentation We describe a patient with inflammation on her legs, which was biopsied and consistent with NL. Treatments, including topical steroids, were started, but there was no improvement, therefore, dupilumab was discussed. She agreed with the treatment and dupilumab injections, and she reported a decrease in redness and improvement in her NL. Conclusion With this report, hopefully, there will be another option for the treatment of NL and different and novel uses for dupilumab.
Authors
- Ryan Sato
- Junko Sato (ORCID: https://orcid.org/0000-0002-9784-5362)
- Hailey Monaco
Institutions
- University of Hawaiʻi at Mānoa (US)
- Northeastern University (US)
- New York Medical College (US)
Publication Details
- Journal
- The Open Dermatology Journal
- Published
- 2024-12-31
- DOI
- https://doi.org/10.2174/0118743722350879241209044938
- Primary Topic
- Skin Diseases and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00